# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ladenburg Thalmann analyst Michael Higgins upgrades Forte Biosciences (NASDAQ:FBRX) from Neutral to Buy and announces $2.75 ...
2023 Operating ResultsResearch and development expenses were $21.9 million for the year ended December 31, 2023, compared to $5...
Funicular Funds has a 5.59% stake in Forte Biosciences
The Dow Jones index closed higher by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their conf...
The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence ...
The Dow Jones closed higher by over 180 points on Wednesday. When insiders purchase or sell shares, it indicates their confiden...